Abstract
The interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential role of nanoscopic devices for molecular imaging of these immune responses. Nanoscopic devices could potentially deliver tracking molecules to DCs, enabling monitoring of DCs and/or T cell activation and tumoricidal activity during immunotherapy, using non-invasive imaging modalities such as nuclear imaging (single photon emission computed tomography (SPECT), positron emission tomography (PET)), magnetic resonance imaging (MRI) and optical imaging.
Keywords: Cancer vaccines, dendritic cells, immunomonitoring, nanotechnology, targeting, Antitumoral immune, nanoscopic devices, tomography, endoscopy, mediastinoscopy, laparoscopy
Current Drug Delivery
Title: Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Volume: 8 Issue: 3
Author(s): Ryan W. Hung, Samar Hamdy, Azita Haddadi, Zahra Ghotbi and Afsaneh Lavasanifar
Affiliation:
Keywords: Cancer vaccines, dendritic cells, immunomonitoring, nanotechnology, targeting, Antitumoral immune, nanoscopic devices, tomography, endoscopy, mediastinoscopy, laparoscopy
Abstract: The interaction of dendritic cells (DCs) and T cells has been the cornerstone of approaches to cancer immunotherapy. Antitumoral immune responses can be elicited by delivering cancer antigens to DCs. As antigen presenting cells, these DCs activate cancer antigen specific T cells. Whereas the first part of the review discusses methods for delivery of cancer vaccines to DCs, in this part the focus is on the potential role of nanoscopic devices for molecular imaging of these immune responses. Nanoscopic devices could potentially deliver tracking molecules to DCs, enabling monitoring of DCs and/or T cell activation and tumoricidal activity during immunotherapy, using non-invasive imaging modalities such as nuclear imaging (single photon emission computed tomography (SPECT), positron emission tomography (PET)), magnetic resonance imaging (MRI) and optical imaging.
Export Options
About this article
Cite this article as:
W. Hung Ryan, Hamdy Samar, Haddadi Azita, Ghotbi Zahra and Lavasanifar Afsaneh, Part II: Targeted Particles for Imaging of Anticancer Immune Responses, Current Drug Delivery 2011; 8 (3) . https://dx.doi.org/10.2174/156720111795256219
DOI https://dx.doi.org/10.2174/156720111795256219 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Circulating MicroRNAs as Potential Biomarkers in Glioma: A Mini-Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Hot Topic: Therapeutic Potential of Fetal Mesenchymal Stem Cells)
Current Stem Cell Research & Therapy The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Kisspeptin Mediated Signaling in Cancer
Current Topics in Medicinal Chemistry Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Expression of P-gp in Glioblastoma: What we can Learn from Brain Development
Current Pharmaceutical Design Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Reflecting Back to Bring Nitric Oxide Research to the Laboratory
Current Medicinal Chemistry A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Glutamate Dehydrogenase as a Promising Target for Hyperinsulinism Hyperammonemia Syndrome Therapy
Current Medicinal Chemistry Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19
Current Pharmaceutical Design HGF-Antagonists: Structure, Activities, and Anti-cancer Approach
Current Signal Transduction Therapy Molecular Mechanisms Regulating mRNA Stability: Physiological and Pathological Significance
Current Genomics CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Current Cancer Drug Targets